Nanobusiness News

RSS
Merrimack to Develop Specialty Pharmaceuticals for Actavis Using its Nanotechnology Platform

Merrimack to Develop Specialty Pharmaceuticals for Actavis Using its Nanotechnology Platform

Pixelligent Technologies Receives SBIT Phase II Grant by Department of Energy (DOE)

Pixelligent Technologies Receives SBIT Phase II Grant by Department of Energy (DOE)

Nanotherapeutics Announces Conclusion of Type C Meeting with the US FDA

Nanotherapeutics Announces Conclusion of Type C Meeting with the US FDA

Leading Research Laboratory in Israel Procures Arrayit’s NanoPrint Microarray Platform

Leading Research Laboratory in Israel Procures Arrayit’s NanoPrint Microarray Platform

Positive CHMP Opinion on ABRAXANE with Gemcitabine for Metastatic Pancreatic Cancer Treatment

Positive CHMP Opinion on ABRAXANE with Gemcitabine for Metastatic Pancreatic Cancer Treatment

Photronics DNP JV to Cater to Taiwan’s Semiconductor Manufacturers

Photronics DNP JV to Cater to Taiwan’s Semiconductor Manufacturers

Dr Garett to Discuss Nanotechnology Importance in Global Markets at Foresight Technical Conference

Dr Garett to Discuss Nanotechnology Importance in Global Markets at Foresight Technical Conference

NanoTech Security CEO, Doug Blakeway to Present at the Southwest IDEAS Investor Conference

NanoTech Security CEO, Doug Blakeway to Present at the Southwest IDEAS Investor Conference

USTC Nanotechnology Center Installing Multiple Plasma Systems

USTC Nanotechnology Center Installing Multiple Plasma Systems

Abakan Completes Phase I of PComP Nanocomposite Coatings Growth Strategy

Abakan Completes Phase I of PComP Nanocomposite Coatings Growth Strategy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.